Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: "The story includes the cost of this test $1,625 and mentions that insurance companies currently don’t cover the cost of the new genetic test for breast cancer. The test manufacturer CEO’s speculation that insurance companies will eventually cover the test because it’s easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. It is not clear how this test improves on these current practice as there was no evidence presented about it. The story appropriately expresses caution when presenting the value of this new test to predict a woman’s lifetime risk of developing cancer. There is a wide range of experts interviewed, all of whom express concern about the current available evidence for the predictive value of this test. Most experts advise against women taking this test, and the American Cancer Society does not promote the test. The story provides appropriate caveats for women who are considering this test. Namely, a lower than average score might suggest a woman could forgo screening. Women with a higher than average risk score could experience unnecessary anxiety and possibly choose treatments they do not need (such as prophylactic mastectomy). The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. Additionally, peer-reviewed studies need to be done to determine the best course of prevention if a woman chooses to take the test and discovers she is at higher risk of developing breast cancer. Because the story raised appropriate questions about the quality of the evidence, we give this a satisfactory score. The story lists the annual incidence of new breast cancers and mortality rate. The story is tempered in reporting about a new genetic test which may or may not be another option for women looking to assess their risk. The story mentions that knowing individual risk may inform a woman’s decision whether to increase surveillance and/or take chemoprevention medication, such as tamoxifen. Several leading breast cancer researchers, a member of the American Cancer Society and a spokesperson for the FDA are interviewed for this story. These interviewees do not have a vested interest in this test–unlike Decode’s chief executive, who is also interviewed, mainly promoting his company’s product. Researchers help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts. The story mentions current prevention guidelines for women who are considered at higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However, the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer  mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. The test discussed in this story has not been studied long enough, nor have results of company studies been subjected to an external review. The focus of the story is a new, widely available genetic test. The story says that any doctor can order this test to assess a woman’s risk of developing of developing one of the more common forms of breast cancer. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there are questions about the validity of tests that have not been subjected to external review. The story notes that there are other genetic tests, but this is one of the first for breast cancer for women who do not carry the BRCA1/2 gene. The story does not mention that there are several other risk calculators to estimate a women’s risk. The story does not rely on the Decode Genetics press release. There is independent reporting and a balanced review of this new genetic test." Claim: Firm says test judges risk for common breast cancers
[A]: "The focus of the story is a newly available genetic test to assess a woman’s risk of developing of developing one of the more common forms of breast cancer. The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there is concern about the validity of such tests that have not been subjected to external review. The test manufacturer CEO’s speculation that insurance companies will eventually cover the test because it’s easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. The story mentions current prevention guidelines for women who are considered higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However,the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. It is not clear how the new genetic test improves on this current practice, as there was no evidence presented. Researchers and clinicians interviewed help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts."


[Q]: Paragraph: Five hours later, Soni was dead, one of more than 100 children to die this month from Acute Encephalitis Syndrome (AES), or ‘brain fever’, in one district of eastern Bihar state. “I still see her in my dreams,” said Sahana Khatun, Soni’s mother. “I can’t accept she is gone.”  The deaths were preventable, doctors say, if poor families had access to good food, clean water and better medical care in Muzaffarpur district, 80 km (50 miles) from the state capital Patna. The epidemic has sparked a debate over growing inequality in India and focused attention on a free healthcare scheme for the poor - known as “Modicare” after Prime Minister Narendra Modi - eight months after it was launched. The precise causes of AES, which killed more than 350 in Bihar in 2014, are not known, though a majority of medical professionals say it is linked to a ferocious heat-wave that has gripped Bihar for the last month. Some studies have blamed toxins in lychees, a fruit grown in abundance in orchards around Muzaffarpur, though many families told Reuters their children had not eaten them in recent weeks. The victims come from poor families who often suffer from malnutrition and dehydration, doctors in Muzaffarpur said. If caught quickly, AES patients can often recover with simple rehydration treatment, doctors said, but delayed care can lead to convulsions and eventual death. “It is a preventable disease,” said Dr. Chaitanya Kumar at the district’s Kejriwal Maternity Hospital, one of two treating young AES patients. “Glucose and providing meals to some of the poorest districts – these are not expensive things.”   India has world-class hospitals in major cities like New Delhi and Mumbai, but rural facilities like those in Muzaffarpur are overstretched, doctors say. The 600-bed Sri Krishna Medical College Hospital in Muzaffarpur has more than 900 patients, a third of them children with AES. Ninety-three AES patients have died at the facility since the outbreak began. Stray goats roam over rubbish and rubble on the hospital grounds. The building has frequent power cuts and the stench of urine lingers in the hallways. The hospital evicted a group of sick inmates from a ward to accommodate the surge in AES patients, but at times there are still two or three children assigned to one bed. “It is incredibly difficult to be a doctor in a place like this,” said Ravikant Singh, a volunteer doctor from Mumbai who was giving rehydration solutions to patients at the hospital. Other doctors said they felt powerless. “I can’t do anything. It is the social conditions that have to change,” said Rajkumar Goenka, secretary of the trust that operates Kejriwal hospital. “The government – state and national – has to do something,” he added. Nearly half of all children in Muzaffarpur are underweight, and a similar number are stunted, or too short for their age, according to government data. In Marwan, a village of thatched huts where many residents belong to one of the lowest rungs in India’s caste system, some children have swollen stomachs – a common sign of malnutrition. Residents interviewed by Reuters said they were unaware of Ayushman Bharat, the program known as ‘Modicare’ launched in 2018 to give India’s poorest free access to private healthcare. Nand Lal Mandhji, 61, whose four-year-old granddaughter died from AES, said the family was given a flyer about the scheme during a hospital visit in May. The family is illiterate and the program was not explained to them, he said. “They gave us something but we didn’t understand what it meant,” he said, clutching the flyer with Modi’s image. Eight families in Marwan with sick relatives said they had never heard of Modicare, and did not receive warnings from authorities about the dangers of AES. “No one comes here. Not politicians, health workers, no one,” said Sahana Khatun, Soni’s mother. ($1 = 69.6350 Indian rupees) Claim: 'Brain fever' blamed for India child deaths preventable: doctors.
[A]: Five-year-old Soni Khatun was playing in the midday sun last week when she began to vomit and lose feeling in her hands. Her mother, a poor laborer living in rural India, borrowed money to take her to hospital.


[Q]: Paragraph: Continental AG announced this week that it has given $5 million to Wildlife Mississippi to finance that organization’s purchase of 1,000 acres along Bayou Pierre west of Hazlehurst in Copiah County. One parcel was purchased from a timber company and one was bought from an individual, said James Cummins, executive director of Wildlife Mississippi The waterway, which empties into the Mississippi River in Claiborne County, is the only home of a fish listed as federally threatened, the bayou darter. Cummins said his group plans to improve habitat by planting native hardwood trees on part of the land which is now planted in pines, and by removing invasive species from areas where there are now hardwoods. The initial restoration work is expected to take place over the winter and spring. Wildlife Mississippi already owns an adjoining 320 acres. “What we’re trying to do is build a larger conservation area around Bayou Pierre,” Cummins said. The stream is plagued by erosion because the channel of the Mississippi is deepening, and Bayou Pierre is carving out a deeper channel of its own to get down to the lower level of the river it feeds into. That’s causing erosion of Bayou Pierre’s banks, harming the stream’s water quality and further stressing the bayou darter. The problem has been going on for years, exacerbated by agriculture and gravel mining in the Bayou Pierre watershed. The U.S. Fish and Wildlife Service has been trying to organize landowners to improve the situation, and Wildlife Mississippi’s entry is one response. Cummins said Wildlife Mississippi was approached by Continental even before the company announced its $1.45 billion tire plant near Clinton in February, and Continental said the transaction was completed in April. “It’s important for Continental to work with local environmental groups to conserve the areas where we’re investing,” Continental Project Manager Grant Bovim said in a statement. Continental ultimately plans 2,500 jobs at the Hinds County site. Wildlife Mississippi will retain the land and is considering public access to the tract in the future. Cummins said the group would like to encourage canoeing and kayaking in Bayou Pierre. ___ Follow Jeff Amy at: http://twitter.com/jeffamy . Read his work at http://bigstory.ap.org/author/jeff-amy . Claim: Tire company gives $5M to protect land around Bayou Pierre.
[A]:
A $5 million donation from the state’s newest major industry will help preserve an environmentally stressed waterway in southwest Mississippi.